Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
BRIEF-Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026 July 30 (Reuters) - Aprea Therapeutics Inc APRE.O:
APREA THERAPEUTICS PROVIDES ACESOT-1051 PROGRAM UPDATE FOR WEE1 INHIBITOR APR-1051: ACCELERATING AND EXPANDING ENROLLMENT. CLINICAL DATA PRESENTATION PLANNED FOR Q4 2026
APREA THERAPEUTICS - ACESOT-1051 ENROLLMENT ACCELERATING TO 6-10 PATIENTS PER MONTH BY Q4 2026
APREA THERAPEUTICS - TO ENROLL AT LEAST 50 PATIENTS WITH USC OR CYCLIN E-OVEREXPRESSING PROC
APREA THERAPEUTICS - ADVANCES APR-1051 IN USC, PROC, AND COMBINATION REGIMENS IN HEAD AND NECK, COLORECTAL CANCER
APREA THERAPEUTICS - ACESOT-1051 CLINICAL SITES EXPAND FROM THREE TO TEN
APREA THERAPEUTICS - DOSE ESCALATION AND BACKFILL EXPANSION EXPECTED TO COMPLETE IN Q2 2027
Source text: ID:nGNX5SqbLS
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing